Bayer, Versant to invest $225 million in biotech venture

TORONTO (Reuters) - German chemicals and healthcare group Bayer said it had set up a joint venture with U.S. life sciences venture capital firm Versant Ventures to invest $225 million in stem cell therapy technology.